PFIZER INC Supplier Finance Program Obligation Current
PFIZER INC (PFE) had Supplier Finance Program Obligation Current of $545.00 million as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:SupplierFinanceProgramObligationCurrent · last filed 2026-08-04
- 2026-06-28: Supplier Finance Program Obligation Current $545.00M.
- 2026-03-29: Supplier Finance Program Obligation Current $518.00M.
- 2025-12-31: Supplier Finance Program Obligation Current $574.00M.
- 2025-09-28: Supplier Finance Program Obligation Current $566.00M.
| Period end | Supplier Finance Program Obligation Current |
|---|---|
| 2026-06-28 | $545.00M 10-Q · filed 2026-08-04 |
| 2026-03-29 | $518.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $574.00M 10-Q · filed 2026-08-04 |
| 2025-09-28 | $566.00M 10-Q · filed 2025-11-04 |
| 2025-06-29 | $501.00M 10-Q · filed 2025-08-05 |
| 2025-03-30 | $546.00M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $688.00M 10-K · filed 2026-02-26 |
| 2024-09-29 | $628.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $593.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $658.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $791.00M 10-K · filed 2026-02-26 |
| 2023-10-01 | $781.00M 10-Q · filed 2023-11-08 |
| 2023-07-02 | $779.00M 10-Q · filed 2023-08-09 |
| 2022-12-31 | $849.00M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |